Interferon-gamma expressing EBV LMP2A-specific T cells for cellular immunotherapy.

Area of Science:

• Immunology
• Cellular Therapy
• Oncology

Background:

• Adoptive immunotherapy aims to enhance anti-tumor immune responses.
• Epstein-Barr virus (EBV) is associated with several malignancies.
• T cells specific to EBV latent membrane protein 2A (LMP2A) are potential therapeutic targets.

Purpose of the Study:

• To enrich and characterize T cells specific for EBV LMP2A for potential adoptive immunotherapy.
• To assess the effector functions and differentiation status of enriched T cells.

Main Methods:

• Enrichment of T cells based on antigen-specific interferon-gamma (IFNγ) production.
• Analysis of T cell specificity, cytokine profiles (Th1/Th2), and cytolytic activity.
• Assessment of T cell surface markers (CD45RO, CD28, CD27, CD45RA) to determine differentiation stage.

Main Results:

• Enriched T cells demonstrated high specificity (>60%) for EBV LMP2A and targeted multiple epitopes.
• Predominant Th1 cytokine production (interleukin-2, granulocyte-macrophage colony-stimulating factor) with minimal Th2 cytokines.
• Enriched T cells exhibited specific lysis of LMP2A-expressing targets via granule exocytosis pathway (IFNγ, CD107 expression).
• Cells displayed a memory phenotype (CD45RO+, CD28+, CD27+, CD45RA-) indicative of self-renewal capacity.

Conclusions:

• IFNγ-based enrichment effectively generates polyclonal, multi-epitope specific T cells targeting EBV LMP2A.
• These T cells possess potent cytotoxic and Th1-skewed effector functions.
• The characterized T cells are suitable for long-term persistence and may enhance efficacy in treating EBV-related malignancies.